Agios Pharmaceuticals, Inc. (AGIO) — Stock Score Summary

Agios Pharmaceuticals, Inc. (AGIO) has a MoatMap StockRank of 28/100 based on Quality (33/100), Value (39/100), and Momentum (44/100) factor scores. The current signal is SELL. Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focusing on rare diseases. It does not operate as a CDMO and lacks the predictable, high-ROIC manufacturing moat required by our CDMO Pricing Power theme.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for genetically defined diseases, particularly in oncology and rare diseases. The company leverages deep expertise in cellular metabolism and a targeted drug discovery approach to address underlying disease mechanisms. Agios has successfully commercialized therapies for rare metabolic disorders and continues to build a pipeline of novel small molecule therapeutics.

Key Financial Metrics

Price$28.14
Market Cap$1.8B
P/E (Forward)-6.27
Price/Book1.54
Return on Equity-32.8%
Return on Invested Capital-38.9%
Debt/Equity3.22
Gross Margin0.0%
Operating Margin-530.3%
Revenue Growth137.7%
Free Cash Flow$-267M

Agios Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Agios Pharmaceuticals, Inc.’s (AGIO) StockRank?
MoatMap’s StockRank for Agios Pharmaceuticals, Inc. (AGIO) is 28/100, with a Sell signal. It is a composite of Quality (33), Value (39), and Momentum (44) factor ranks across MoatMap’s 19,000+ stock universe.
Does Agios Pharmaceuticals, Inc. have an economic moat?
Agios Pharmaceuticals, Inc. (AGIO) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Agios Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Agios Pharmaceuticals, Inc. (AGIO) is Sell, based on a StockRank of 28/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Agios Pharmaceuticals, Inc. in?
Agios Pharmaceuticals, Inc. (AGIO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksAGIO deep dive reportAI ChampionsHow we score stocksSense-check another stock